Contributions
Abstract: P1063
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Introduction: Brain volume measurements are becoming an important tool for assessing success in controlling multiple sclerosis (MS) activity. MSmetrix (Icometrix) is an easy-to-use platform, specific for MS magnetic resonance imaging (MRI) of the brain. It provides data on total brain volume, grey matter volume and lesion load volume. The objective of the present study was to assess whether disability, cognition, disease duration, recent use of corticosteroids and the number of relapses during the previous year correlated with brain volume measurements from MSmetrix.
Material and methods: Data on 185 Icometrix reports from patients with MS (with detailed medical records) were used to evaluate the potential correlation between brain volume measurements and clinical parameters.
Results: Disease duration and disability showed significant negative correlations with total brain volume (p< 0.001) and grey matter volume (p< 0.001). Worse cognition performance was independently associated with lower brain volume (p< 0.001), lower grey matter volume (p< 0.001), higher disability (p< 0.001), longer disease duration (p< 0.001) and greater number of relapses in the previous year (p=0.019). Increased lesion load in the brain and greater number of relapses in the previous year were also independently correlated with decreased brain tissue volume (p< 0.001) and with increased disability (p< 0.001). Recent relapses and corticosteroid use were associated with higher grey matter volume (p=0.04). Patients' gender did not influence the brain volume findings.
Conclusion: This is the first large study with real-world data to show that Icometrix is a relevant tool for studying brain volume loss in MS.
Acknowledgments: Reports from icometrix were sponsored by an unconditional grant from Novartis. There are no conflicts of interest to declare regarding this abstract.
Yara Dadalti Fragoso and Paulo Roberto Wille on behalf of the Brazilian Brain Volume Studies (B-BRAVOS) group (Marcelo Abreu, Joseph Bruno B. Brooks, Ronaldo Maciel Dias, Juliana Avila Duarte, Luciano Farage, Alessandro Finkelsztejn, Alan Christmann Frohlich, Marcus Vinicius M. Goncalves, Bruno V. Sobreira Guedes, Leonardo Medeiros, Rodrigo Andre Oliveira, Flavio Diniz Ribas, Fernando Coronetti G. Rocha, Gutemberg Augusto C. Santos, Claudio Scorcine, Guilherme Lopes da Silveira, Carina Tellaroli Spedo, Carlos Bernardo Tauil, Juliana Santos Varela, Vera L. Ferreira Vieira) have no conflicts of interest to declare.
Disclosure: The authors have no conflict of interest to declare.
Abstract: P1063
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Introduction: Brain volume measurements are becoming an important tool for assessing success in controlling multiple sclerosis (MS) activity. MSmetrix (Icometrix) is an easy-to-use platform, specific for MS magnetic resonance imaging (MRI) of the brain. It provides data on total brain volume, grey matter volume and lesion load volume. The objective of the present study was to assess whether disability, cognition, disease duration, recent use of corticosteroids and the number of relapses during the previous year correlated with brain volume measurements from MSmetrix.
Material and methods: Data on 185 Icometrix reports from patients with MS (with detailed medical records) were used to evaluate the potential correlation between brain volume measurements and clinical parameters.
Results: Disease duration and disability showed significant negative correlations with total brain volume (p< 0.001) and grey matter volume (p< 0.001). Worse cognition performance was independently associated with lower brain volume (p< 0.001), lower grey matter volume (p< 0.001), higher disability (p< 0.001), longer disease duration (p< 0.001) and greater number of relapses in the previous year (p=0.019). Increased lesion load in the brain and greater number of relapses in the previous year were also independently correlated with decreased brain tissue volume (p< 0.001) and with increased disability (p< 0.001). Recent relapses and corticosteroid use were associated with higher grey matter volume (p=0.04). Patients' gender did not influence the brain volume findings.
Conclusion: This is the first large study with real-world data to show that Icometrix is a relevant tool for studying brain volume loss in MS.
Acknowledgments: Reports from icometrix were sponsored by an unconditional grant from Novartis. There are no conflicts of interest to declare regarding this abstract.
Yara Dadalti Fragoso and Paulo Roberto Wille on behalf of the Brazilian Brain Volume Studies (B-BRAVOS) group (Marcelo Abreu, Joseph Bruno B. Brooks, Ronaldo Maciel Dias, Juliana Avila Duarte, Luciano Farage, Alessandro Finkelsztejn, Alan Christmann Frohlich, Marcus Vinicius M. Goncalves, Bruno V. Sobreira Guedes, Leonardo Medeiros, Rodrigo Andre Oliveira, Flavio Diniz Ribas, Fernando Coronetti G. Rocha, Gutemberg Augusto C. Santos, Claudio Scorcine, Guilherme Lopes da Silveira, Carina Tellaroli Spedo, Carlos Bernardo Tauil, Juliana Santos Varela, Vera L. Ferreira Vieira) have no conflicts of interest to declare.
Disclosure: The authors have no conflict of interest to declare.